Characterization of gut microbiome composition in T2D patients under SGLT2i and GLP1RA treatment
| dc.contributor.advisor | Org, Elin, juhendaja | |
| dc.contributor.advisor | Krigul, Kertu Liis, juhendaja | |
| dc.contributor.author | Kazimova, Valida | |
| dc.date.accessioned | 2023-06-21T08:08:08Z | |
| dc.date.available | 2023-06-21T08:08:08Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Type 2 Diabetes (T2D) is a globally recognized health concern that has garnered significant research attention. This thesis work focuses on gut microbiome analysis in T2D patients who start taking two medications antidiabetic drugs: Empaglifrozin (SGLT2i) and Semaglutide (GLP1RA). Microbiome composition was analyzed using 16S rRNA sequencing. The research aims to enhance our understanding of how the gut microbiome is related to SGLT2/GLP1 drug intake, potentially leading to the development of personalized treatment approaches for improved patient outcomes. | et |
| dc.identifier.uri | https://hdl.handle.net/10062/90897 | |
| dc.language.iso | eng | et |
| dc.publisher | Tartu Ülikool | et |
| dc.rights | openAccess | et |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Type 2 Diabetes | et |
| dc.subject | SGLT2i | et |
| dc.subject | GLP1RA | et |
| dc.subject | gut microbiome | et |
| dc.subject | Empaglifrozin | et |
| dc.subject | Semaglutide | et |
| dc.title | Characterization of gut microbiome composition in T2D patients under SGLT2i and GLP1RA treatment | et |
| dc.type | Thesis | et |